Maxtar Bio Genics

What Maxtar Bio Genics does

Maxtar Bio Genics is a privately held, family-run pharmaceutical manufacturer headquartered in Baddi, Himachal Pradesh, India. Founded in 1991 by Jagdish Bansal, the company operates a WHO-GMP certified manufacturing complex spanning over 100,000 sq. ft. in Baddi plus a 50,000 sq. ft. Schedule M-compliant facility in Delhi, producing generic tablets, capsules, and effervescent formulations across General and Beta-Lactam categories. Daily production capacity is 5 million tablets and 0.5 million capsules, supported by in-house formulation development, analytical, microbiological, and stability laboratories, and an in-house packaging unit.

The company generates revenue across four streams: (1) direct B2B export sales to pharmaceutical importers, distributors, and marketing companies across 30+ countries in Latin America, Africa, Asia, and CIS regions, backed by 150+ product dossiers ready for registration and country-specific approvals (NAFDAC, Philippines FDA, Ghana, Vietnam, Ivory Coast, Malawi); (2) third-party/contract manufacturing with private labeling and customized packaging for marketing companies; (3) domestic branded generics through its wholly-owned sister concern Arika Healthcare, distributing 120+ products via 50+ distributors across 24+ Indian states; and (4) direct-to-consumer medical-device e-commerce (glucometers, nebulizers, BP monitors, mobility aids). The GTM motion is sales-led with dedicated regulatory affairs teams handling CTD/ACTD dossiers and segment-specific approvals, supplemented by industry exhibitions and content marketing.

The business is currently investing in an EU-GMP upgrade of its tablets/capsules unit and planning a sterile injectables facility, signaling an intent to move from semi-regulated export markets into higher-barrier regulated geographies and higher-value dosage forms. Five named enterprise customers (Micro Labs, Morepen, Shalina Healthcare, Aravis Pharmaceuticals, Asmoh Laboratories) and Government of India Star Export House recognition (2021) anchor the export franchise. No external institutional capital, public listing, or AI/ML capability is disclosed in the source data.

Name

Maxtar Bio Genics

Legal name

Maxtar Biogenics

Website

https://maxtarbiogenics.com

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

251–500 employees

Short description

Maxtar Bio Genics is a privately held Indian pharmaceutical manufacturer producing WHO-GMP certified generic tablets, capsules, and effervescent formulations for export to 30+ countries, contract manufacturing partners, domestic branded generics via Arika Healthcare, and consumer medical devices through its website.

Ownership category

akta.pro rank

Product category

Generic Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

akta.pro secondary industries

Packaging, Labeling & Serialization Services (biologics/cold chain) (HLAAAKAJ), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Generic pharmaceutical manufacturing
• Contract pharmaceutical manufacturing
• Tablet capsule manufacturing
• WHO-GMP certified manufacturing
• Medical device supplies

Headquarters

HQ city

Delhi

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Manufacturing: Manufacturing and supply of high-quality tablets and capsules through GMP-compliant practices. Daily production capacity of 5 million tablets and 0.5 million capsules. Serves domestic, export, and third-party markets.
2. Third-Party/Contract Manufacturing: Provides third-party and contract manufacturing services including private labeling and customized packaging options tailored to market or client needs.
3. Domestic Branded Generics: Through sister concern Arika Healthcare, sells 120+ branded generic products across India via 50+ distributors to pharmacies and healthcare providers.
4. Medical Devices E-commerce: Direct-to-consumer sales of medical devices including glucometers, blood pressure monitors, nebulizers, and mobility products through company website storefront.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Maxtar Bio Genics manufactures WHO-GMP certified generic pharmaceutical tablets, capsules, and effervescent formulations across General and Beta-Lactam categories, producing 5 million tablets and 0.5 million capsules daily at its Baddi facility. The company supplies international pharmaceutical importers, distributors, and marketing companies across 30+ countries, provides third-party and contract manufacturing services with private labeling, and sells branded generics domestically via its sister concern Arika Healthcare. It also retails medical devices (glucometers, nebulizers, mobility aids) directly to consumers through its e-commerce storefront.

Product overview

Maxtar Bio Genics operates as a pharmaceutical company with two main product lines: (1) WHO-GMP certified pharmaceutical manufacturing of generic tablets and capsules across therapeutic categories including antibiotics, cardiovascular, anti-malarial, analgesics, respiratory, and gastrointestinal medications, with capabilities in both General and Beta-Lactam categories; and (2) medical devices and mobility enhancers including blood oxygen monitors, glucometers, nebulizers, blood pressure monitors, thermometers, knee braces, shoulder slings, back braces, and quad canes sold under the DO Medical Equipment brand. The company also operates Arika Healthcare as its domestic branded generics division serving the Indian market with 120+ products, and provides third-party/contract manufacturing services.

Differentiator

Problem solved

Functional benefit

Brands

• Arika Healthcare: Domestic branded generics division of Maxtar Bio-Genics offering 120+ products across key therapeutic areas for the Indian market, supported by WHO-cGMP manufacturing excellence.

Products and services

• Pharmaceutical Tablets and Capsules WHO-GMP certified generic pharmaceutical tablets and capsules manufactured across multiple therapeutic categories including antibiotics, cardiovascular, anti-malarial, analgesics, respiratory, and gastrointestinal medications, available in both General and Beta-Lactam categories. Targeted at international pharma importers, distributors, and marketing companies.
• Effervescent Formulations Specialized effervescent tablet formulations manufactured under WHO-GMP certification, offered as part of the broader pharmaceutical product portfolio for B2B clients.
• Third-Party and Contract Manufacturing Services GMP-compliant contract manufacturing services for pharmaceutical marketing companies, including private labeling and customized packaging options tailored to client or market needs. Supports domestic, export, and third-party markets.
• Arika Healthcare Branded Generic Pharmaceuticals Domestic branded generics division of Maxtar Bio Genics offering 120+ pharmaceutical products across key therapeutic areas (analgesics, anti-diabetics, anti-infectives, cardiovascular, and respiratory medications) for the Indian market, distributed through 50+ distributors across 24+ states to pharmacies and healthcare providers.
• Diagnostic Medical Devices (Blood Oxygen Monitor, Glucometer, Blood Pressure Monitor, Contactless Thermometer) Diagnostic medical devices sold directly to consumers via the company e-commerce storefront, including Blood Oxygen Monitor (₹62), Glucometer (₹52), Blood Pressure Monitor (₹92), and Contactless Thermometer (₹38) for personal health monitoring at home.
• Respiratory Care Devices (Nebulizers, Inhaler) Respiratory care devices for personal and home use, including Jet Nebulizer (₹110), Nebulizer (₹58 sale price), Portable Jet Nebulizer, and Inhaler (₹27 sale price), sold through the company website storefront.
• Orthopedic and Mobility Aids (Knee Brace, Shoulder Sling, Back Brace, Quad Cane) Orthopedic support and mobility aids for personal use, including Hinged Knee Brace (₹180), Orthopedic Back Brace (₹55), Shoulder Sling (₹75), and Quad Cane (₹70 sale price), sold through the company website storefront.

Quantifiable outcome

• 500+ product formulations and 150+ product dossiers ready for global registration
• +2 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Arika HealthcarecoreOthersSister concern of Maxtar Biogenics established to cater to the Indian domestic generic pharmaceutical market. Built on the same foundation of quality, compliance, and ethical practices, Arika Healthcare focuses on delivering high-quality, affordable medicines across diverse therapeutic segments. Operates with 120+ branded generic products and 50+ distributors pan-India.

Scale indicators9 records

Recent moves12 records

Expansion highlights5 records

Broad incumbents

• Cipla: Major Indian generic manufacturer with deep emerging-market reach across Africa, Asia and Latin America; comparable in finished dosage form manufacturing, multi-country regulatory dossiers, and B2B export-led model.
• Aurobindo Pharma: One of India's largest generic manufacturers and exporters with strong presence in Africa, Latin America and emerging markets; comparable as a vertically integrated Indian pharma company serving similar regulatory regimes with finished oral solid doses.
• Dr. Reddy's Laboratories: Indian pharma major with global generic finished-dose manufacturing and strong emerging-markets franchise; comparable in WHO-GMP oral solid manufacturing for export and integrated regulatory operations.
• Lupin Pharmaceuticals: Indian generics leader with significant API-to-formulation integration and extensive emerging-market presence; comparable manufacturing scale, regulatory breadth, and contract manufacturing capabilities.

Direct peers

• Micro Labs Limited: Indian generics company with broad therapeutic portfolio and global export reach across emerging and semi-regulated markets; comparable finished-dose manufacturing and international regulatory footprint, and named as a current Maxtar customer.
• Unichem Laboratories: Mid-sized Indian generics manufacturer focused on oral solid finished dosages with international regulatory approvals; comparable scale, dosage form focus, and export-led GTM.
• Ipca Laboratories: Indian generics manufacturer with strong anti-malarial/therapeutic breadth and export footprint in Africa/Asia; comparable product mix (oral solids for infectious disease), API-formulation integration, and emerging-market regulatory coverage.
• Strides Pharma: Indian pharma company with finished-dose manufacturing for emerging markets (notably Africa via subsidiary) and strong B2B/contract manufacturing; comparable in destination markets, dosage forms, and channel partnerships.
• Morepen Laboratories: Indian pharma manufacturer with API and finished-dose capabilities and active export business; comparable in product categories, manufacturing capabilities, and even listed as a current Maxtar customer, indicating direct operational overlap.
• Emcure Pharmaceuticals: Indian mid-sized generic manufacturer with strong B2B contract manufacturing and emerging-markets export orientation; closely comparable in scale, customer mix (pharma marketing companies, third-party manufacturing), and therapeutic breadth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/maxtarbiogenics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Maxtar Bio Genics